{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2021_00016259", "CSN": null, "TRF": "ORD_1182592_01", "MRN": "28052746", "PhysicianId": "49551", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "883319", "clinicalId": "884724", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1182592_01", "SampleName": "US1143571.01", "Version": "0", "Sample": {"FM_Id": "ORD_1182592_01", "SampleId": "US1143571.01", "BlockId": "S109-75098C", "TRFNumber": "ORD_1182592_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "Blood", "ReceivedDate": "2021_09_07", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}]}, "TumorPurity": "30", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S110-99531", "MRN": "28052746", "FullName": "\u6c5f\u9686\u5bb6", "FirstName": "Lung_Chia", "LastName": "Chiang", "SubmittedDiagnosis": "Metastatic adenocarcinoma, Lung", "Gender": "Male", "DOB": "1947_01_25", "OrderingMD": "\u9127\u8c6a\u5049", "OrderingMDId": "49551", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Lung", "CollDate": "2020_01_08", "ReceivedDate": "2021-09-16 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Adenocarcinoma, NOS"}, "PertinentNegatives": {"PertinentNegative": [{"Gene": "BRAF"}, {"Gene": "NRAS"}]}, "Summaries": {"alterationCount": "21", "clinicalTrialCount": "10", "resistiveCount": "2", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "ARID1A", "isVUS": "true", "variantName": "S90G"}, {"geneName": "BRIP1", "isVUS": "true", "variantName": "I896V"}, {"geneName": "FGF6", "isVUS": "true", "variantName": "D103E"}, {"geneName": "FLCN", "isVUS": "true", "variantName": "D476E"}, {"geneName": "MSH3", "isVUS": "true", "variantName": "A62_P63insAAA"}, {"geneName": "NBN", "isVUS": "true", "variantName": "rearrangement"}, {"geneName": "NOTCH3", "isVUS": "true", "variantName": "D1598V"}, {"geneName": "NTRK1", "isVUS": "true", "variantName": "E275A"}, {"geneName": "P2RY8", "isVUS": "true", "variantName": "A143T"}, {"geneName": "PTPRO", "isVUS": "true", "variantName": "P1015L"}, {"geneName": "SUFU", "isVUS": "true", "variantName": "M141I"}, {"geneName": "TGFBR2", "isVUS": "true", "variantName": "N63S"}, {"geneName": "TYRO3", "isVUS": "true", "variantName": "R490C"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "KRAS", "Include": "true", "Alterations": {"Alteration": {"Name": "G12D", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "G12D"}}, "Interpretation": "KRAS encodes a member of the RAS family of small GTPases. Activating mutations in RAS genes can cause uncontrolled cell proliferation and tumor formation (Pylayeva_Gupta et al., 2011; 21993244, Kahn et al., 1987; 3310850). KRAS alterations affecting amino acids G12, G13, Q22, P34, A59, Q61, and A146, as well as mutations G10_A11insG, G10_A11insAG (also reported as G10_A11dup and G12_G13insAG), A18D, L19F, D33E, G60_A66dup/E62_A66dup, E62K, and K117N have been characterized as activating and oncogenic (Akagi et al., 2007; 17150185, Bollag et al., 1996; 8955068, Buhrman et al., 2010; 20194776, Colicelli, 2004; 15367757, Edkins et al., 2006; 16969076, Feig and Cooper, 1988; 3043178, Gremer et al., 2011; 20949621, Janakiraman et al., 2010; 20570890, Kim et al., 2016; 27147599, Lukman et al., 2010; 20838576, Naguib et al., 2011; 21371307, Prior et al., 2012; 22589270, Priv\u00e9 et al., 1992; 1565661, Pylayeva_Gupta et al., 2011; 21993244, Scheffzek et al., 1997; 9219684, Scholl et al., 2009; 19490892, Smith et al., 2010; 20147967, Tyner et al., 2009; 19075190, Valencia et al., 1991; 2029511, White et al., 2016; 26854029, Wiest et al., 1994; 8058307, Kim et al., 2016; 27147599, Angeles et al., 2019; 31289513, Tong et al., 2014; 24642870). Mutations in KRAS have been reported in approximately 35_50% of colorectal cancers (CRCs) (Lievre et al., 2006; 16618717, De Roock et al., 2011; 21163703, Chen et al., 2014; 25367198, Li et al., 2015; 25929517, Hu et al., 2016; 27977612, Zekri et al., 2017; 28218784, Staudacher et al., 2017; 29048416, Wang et al., 2018; 29705968, Guo et al., 2018; 29666387). Numerous studies have reported that KRAS mutations are associated with increased metastasis, adverse clinicopathological features, and shorter survival of patients with CRC (Chen et al., 2014; 25367198, Li et al., 2015; 25929517, Hu et al., 2016; 27977612, M\u00e1rmol et al., 2017; 28106826, Zekri et al., 2017; 28218784, Kwak et al., 2017; 28858102). Preclinical evidence suggests that KRAS activation may predict sensitivity to MEK inhibitors, such as trametinib, binimetinib, cobimetinib, and selumetinib (Nakano et al., 1984; 6320174, Pylayeva_Gupta et al., 2011; 21993244, Yamaguchi et al., 2011; 21523318, Watanabe et al., 2013; 23438367, Gilmartin et al., 2011; 21245089, Yeh et al., 2009; 19372556). However, multiple clinical trials have reported lack of efficacy of trametinib and other MEK inhibitors when used as monotherapy for treatment of patients with KRAS_mutant CRC (Tsimberidou et al., 2013; ASCO Abstract e22086)(Infante et al., 2012; 22805291, Zimmer et al., 2014; 24947927, Bennouna et al., 2011; 20127139, Weekes et al., 2013; 23434733). Both clinical (Hochster et al., 2013; ASCO GI Abstract 380, Juric et al., 2014; ASCO Abstract 9051) and preclinical (Lamba et al., 2014; 25199829, Sun et al, 2014; 24685132) studies suggest that combinatorial approaches including MEK inhibitors are likely to be more effective for the treatment of CRC, including strategies such as combination of MEK inhibitors with PI3K inhibitors (Juric et al., 2014; ASCO Abstract 9051), RAF inhibitors (Lamba et al., 2014; 25199829), pan_ERBB inhibitors (Sun et al, 2014; 24685132), or chemotherapeutic agents (Hochster et al., 2013; ASCO GI Abstract 380). Preclinical and clinical data suggest that KRAS mutations may predict clinical benefit from SHP2 inhibitors (Lu et al., 2019; 31068384, Mainardi et al., 2018; 29808006, Koczywas et al., 2021; AACR Abstract LB001, Brana et al., 2021; ASCO Abstract 3005, Bendell et al., 2020; EORTC_NCI_AACR Abstract 5). A Phase 1 study of RMC_4630 for relapsed/refractory solid tumors reported a DCR of 58% (23/40) for patients with NSCLC and KRAS mutations and a DCR of 75% (12/16) for patients with NSCLC and KRAS G12C mutations (Koczywas et al., 2021; AACR Abstract LB001). Interim results from a Phase 1/2 study of RMC_4630 plus cobimetinib reported tumor reduction in 3 of 8 patients with KRAS_mutated colorectal cancer (Bendell et al., 2020; EORTC_NCI_AACR Abstract 5). Preclinical and limited clinical evidence suggest that KRAS mutation may predict sensitivity to PLK1 inhibitors (Luo et al., 2009; 19490893, Lenz et al., 2020; ASCO GI Abstract TPS265). A Phase 1b/2 study of PLK1 inhibitor onvansertib in combination with FOLFIRI and bevacizumab for patients with KRAS_mutated metastatic CRC previously treated with chemotherapy reported an 87.5% (7/8; 3 PR, 4 SD) clinical benefit rate, with 1 patient going on to successful curative surgery (Barzi et al., 2020; AACR Abstract CT235). The reovirus Reolysin targets cells with activated RAS signaling (Strong et al., 1998; 9628872, Coffey et al., 1998; 9812900, Gong and Mita, 2014; 25019061) and is in clinical trials for patients with some tumor types. Reolysin has demonstrated mixed clinical efficacy, with the highest rate of response reported for patients with head and neck cancer (Forsyth et al., 2008; 18253152, Vidal et al., 2008; 18981012, Gollamudi et al., 2010; 19572105, Harrington et al., 2010; 20484020, Comins et al., 2010; 20926400, Lolkema et al., 2011; 21106728, Galanis et al., 2012; 22871663, Karapanagiotou et al., 2012; 22316603, Morris et al., 2013; 22886613). Activating mutations in KRAS or NRAS are associated with lack of clinical benefit from cetuximab (Van Cutsem et al., 2011; 21502544, Bokemeyer et al., 2011; 21228335, Karapetis et al., 2008; 18946061, De Roock et al., 2008; 17998284) or panitumumab (Douillard et al., 2014; 24718886, Douillard et al., 2012; 24024839, Amado et al., 2008; 18316791) for patients with CRC. Therefore, activating mutations in either gene indicate against the use of cetuximab and panitumumab (NCCN Guidelines v.3.2018).", "Include": "true", "ClinicalTrialNote": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. KRAS mutation may predict sensitivity to PLK1 inhibitors. Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant colorectal cancer; combination therapies may be more effective.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Cetuximab", "FDAApproved": "true", "Rationale": "<p><b>Approved Indications:</b> Cetuximab is a monoclonal antibody that targets EGFR. It is FDA approved for the treatment of head and neck squamous cell carcinoma (HNSCC) and KRAS_wild_type, EGFR_expressing metastatic colorectal cancer (CRC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> Therapies targeting EGFR, including cetuximab, have been shown to have significant clinical activity for patients with CRC (Bokemeyer et al., 2011; 21228335, Cunningham et al., 2004; 15269313, De Roock et al., 2008; 17998284, Jonker et al., 2007; 18003960, Karapetis et al., 2008; 18946061, Van Cutsem et al., 2011; 21502544); wild_type KRAS and NRAS are predictive biomarkers for the efficacy of cetuximab in metastatic CRC (NCCN Colon Cancer Guidelines v2.2021). Activating mutations in either KRAS (Van Cutsem et al., 2011; 21502544, Bokemeyer et al., 2011; 21228335, Karapetis et al., 2008; 18946061, De Roock et al., 2008; 17998284) or NRAS (Di Bartolomeo et al., 2013; 23821376, De Roock et al., 2010; 20619739), which function downstream of EGFR, are associated with lack of benefit of cetuximab for patients with CRC and indicate against the use of cetuximab (NCCN Guidelines v2.2019). </p> <p><b>Supporting Data:</b> Cetuximab has been shown to improve OS, PFS, and response rate for patients with KRAS_wild_type CRC, both as first_line combination therapy with FOLFIRI or FOLFOX4 (Van Cutsem et al., 2011; 21502544, Bokemeyer et al., 2011; 21228335, Jonker et al., 2007; 18003960) and as monotherapy or combination therapy with irinotecan for chemotherapy_refractory patients (Cunningham et al., 2004; 15269313, De Roock et al., 2008; 17998284, Karapetis et al., 2008; 18946061). A prospective study of first_line cetuximab for patients with KRAS/NRAS/BRAF mutation_negative metastatic CRC resulted in limited efficacy, with 10.5% (2/19) of participants experiencing PRs and 57.9% (11/19) experiencing SDs (Moiseyenko et al., 2018; 29470838). The Phase 2 AVETUX trial of cetuximab combined with avelumab and mFOLFOX6 for patients with RAS_ and BRAF_wild_type metastatic CRC resulted in an ORR of 79.5% (6 CR and 25 PRs, n=39) and a DCR of 92.3% (Stein et al., 2020; ASCO GI Abstract 96). In the Phase 3 ASPECCT study, panitumumab was found to be non_inferior to cetuximab with respect to median OS (10.4 vs. 10.0 months, HR=0.97) for patients with previously treated KRAS exon 2 wildtype metastatic colorectal cancer; median PFS was also similar between the two treatment groups (4.4 vs. 4.1 months, HR=1.00)(Price et al., 2014; 24739896). In a similar patient population, a Phase 2 study of combination panitumumab and irinotecan versus combination cetuximab and irinotecan also demonstrated non_inferiority with respect to median PFS (5.4 vs. 4.3 months, HR = 0.64) and median OS (14.9 vs. 11.5 months, HR=0.66)(Sakai et al., 2020; 32526634). </p>", "ApprovedUses": null, "Effect": "Resistant", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Panitumumab", "FDAApproved": "true", "Rationale": "<p><b>Approved Indications:</b> Panitumumab is a monoclonal antibody that targets EGFR. It is FDA approved to treat KRAS wild_type and NRAS wild_type metastatic colorectal cancer (CRC) combined with chemotherapy or as monotherapy for patients who have progressed on prior chemotherapy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> Therapies targeting EGFR, including panitumumab, have been shown to have significant clinical activity for patients with CRC (Douillard et al., 2014; 24718886, Price et al., 2014; 24739896, Van Cutsem et al., 2007; 17470858); wild_type KRAS and NRAS are predictive biomarkers for the efficacy of panitumumab in metastatic CRC (NCCN Colon Cancer Guidelines v2.2021). Activating mutations in either KRAS (Douillard et al., 2014; 24718886, Douillard et al., 2012; 24024839, Amado et al., 2008; 18316791) or NRAS (Douillard et al., 2013; 24024839, Peeters et al., 2013; 23325582), which function downstream of EGFR, are associated with lack of benefit of panitumumab for patients with CRC and indicate against the use of panitumumab (NCCN Guidelines v2.2019). </p> <p><b>Supporting Data:</b> In the Phase 3 ASPECCT study, panitumumab was found to be non_inferior to cetuximab with respect to median OS (10.4 vs. 10.0 months, HR=0.97) for patients with previously treated KRAS exon 2 wildtype metastatic colorectal cancer; median PFS was also similar between the two treatment groups (4.4 vs. 4.1 months, HR=1.00)(Price et al., 2014; 24739896). In a similar patient population, a Phase 2 study of combination panitumumab and irinotecan versus combination cetuximab and irinotecan also demonstrated non_inferiority with respect to median PFS (5.4 vs. 4.3 months, HR = 0.64) and median OS (14.9 vs. 11.5 months, HR=0.66)(Sakai et al., 2020; 32526634). Panitumumab has been shown to improve OS, PFS, and ORR for patients with KRAS wild_type CRC, both as first_line combination therapy with FOLFOX4 (Douillard et al., 2014; 24718886) and as monotherapy for chemotherapy_refractory patients (Price et al., 2014; 24739896, Van Cutsem et al., 2007; 17470858). An open_label, randomized Phase 2 trial reported that for patients with unresectable RAS_wild_type colorectal adenocarcinoma treated with first_line panitumumab plus FOLFOX4, maintenance with a combination of panitumumab plus fluorouracil and leucovorin was superior to panitumumab monotherapy (10_month PFS 59% vs. 49%)(Pietrantonio et al., 2019; 31268481). </p>", "ApprovedUses": null, "Effect": "Resistant", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT03989115", "Include": "true"}, {"nctId": "NCT03284502", "Include": "true"}, {"nctId": "NCT04303403", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT02079740", "Include": "true"}, {"nctId": "NCT03905148", "Include": "true"}, {"nctId": "NCT04111458", "Include": "true"}, {"nctId": "NCT03374254", "Include": "true"}, {"nctId": "NCT03829410", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "APC", "Include": "true", "Alterations": {"Alteration": {"Name": "S1276*, E1379*", "AlterationProperties": {"AlterationProperty": [{"isEquivocal": "false", "name": "S1276*"}, {"isEquivocal": "false", "name": "E1379*"}]}, "Interpretation": "APC (adenomatous polyposis coli) encodes a tumor suppressor with critical roles in regulating cell division and adhesion. APC interacts with beta_catenin and controls signaling in the WNT pathway, which regulates embryonic development and cell differentiation (Logan and Nusse, 2004; 15473860). Alterations such as seen here may disrupt APC function or expression (Eklof et al., 2001; 11707392, Liu et al., 2006; 16753179, Dikovskaya et al., 2010; 20144988, Murphy et al., 2007; 17410430, Aretz et al., 2004; 15459959). APC alterations have been found in 77% of tumors in the Colorectal Adenocarcinoma TCGA dataset (Cancer Genome Atlas Network., 2012; 22810696). Inactivation of APC leads to activation of the Wnt/beta_catenin pathway, which is thought to play a role in the adenoma_carcinoma transition in some cancers, including colorectal cancer (CRC) (Fu et al., 2011; 21455986). The prognostic significance of APC mutations in sporadic CRC remains unclear (Quyn et al., 2008; 19110823). Solid tumors with WNT/beta_catenin pathway alterations, as seen here, were observed to have significantly less T_cell inflammation in one study (Luke et al., 2019; 30635339). There are no approved drugs targeted to APC defects or WNT upregulation in solid tumors. Preclinical studies have reported that APC inactivation or beta_catenin activation confer synthetic lethality when TRAIL receptors are upregulated and the TRAIL death receptor program is activated (Zhang et al., 2010; 20348907). In addition, the COX_2 inhibitor celecoxib was shown to reduce WNT signaling in cancer cell lines (Lu et al., 2009; 19026633, Tuynman et al., 2008; 18281498). A preclinical study has found that a small_molecule tankyrase inhibitor shows some activity in APC_mutant CRC models (Lau et al., 2013; 23539443). Germline mutations in APC are found in more than 90% of patients with familial adenomatous polyposis (FAP) (Kerr et al., 2013; 23159591, Fearon, 2011; 21090969, Kastritis et al., 2009; 18844223). The prevalence for FAP in the general population is estimated to be 1:8,300 from birth (Half et al., 2009; 19822006), and in the appropriate clinical context germline testing of APC is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "CASP8", "Include": "true", "Alterations": {"Alteration": {"Name": "G20fs*18", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "G20fs*18"}}, "Interpretation": "CASP8 encodes caspase_8, a multifunctional protein that mediates apoptosis (Galluzzi et al., 2016; 26885855, Tummers and Green, 2017; 28462525, Crowder and El_Deiry, 2012; 23070000, Liu et al., 2011; 21801448), cell motility (Graf et al., 2014; 24467204, Barbero et al., 2009; 19383910), and cell signaling, including through the NFkB (Zhang et al., 2015; 25446254, Su et al., 2005; 15746428, Henry and Martin, 2017; 28212752) and MAPK (Kober et al., 2011; 21975294, Sun et al., 2011; 21152872) pathways. The role of CASP8 in cancer is complex and context_dependent, with diverse cancer types exhibiting either overexpression or loss of expression. CASP8 mutations found in the context of cancer tend to be truncating or missense mutations; the majority of the characterized mutations impair apoptosis (Soung et al., 2005; 15705878, Soung et al., 2005; 15531912, Mandruzzato et al., 1997; 9271594, Kim et al., 2003; 12949717, Li et al., 2014; 24816188) and promote NFkB activation (Ando et al., 2013; 23659359). Germline polymorphisms in CASP8, including both coding and non_coding alterations, have been correlated with either reducing or increasing risk of various cancers (Zhang et al., 2013; 23479148, Chen et al., 2012; 23170140, Cai et al., 2017; 28915630) including breast (Zhang et al., 2017; 28674227, Ji et al., 2014; 25553350, Cai et al., 2017; 28915630), prostate (Stacey et al., 2016; 26740556, Tsuchiya et al., 2013; 23946871), ovarian (Engel et al., 2010; 20978178, Latif et al., 2010; 20502973, Ma et al., 2011; 21714991), renal cell (Cai et al., 2017; 28915630, De Martino et al., 2013; 23313206, Zhu et al., 2010; 20572163), colorectal (Cai et al., 2017; 28915630, Zhang et al., 2012; 22513478), gastric (Hyland et al., 2014; 23921907, Mocellin et al., 2015; 25731870), esophageal (Zhao et al., 2017; 28542283, Hyland et al., 2015; 26635288, Yin et al., 2014; 24464182), lung (Ji et al., 2014; 25553350, Zhao et al., 2017; 28542283), cervical (Cai et al., 2017; 28915630, Chattopadhyay et al., 2015; 26458812), bladder (Wang et al., 2009; 19276244, Cai et al., 2017; 28915630), and basal cell (Stacey et al., 2015; 25855136) carcinomas, as well as chronic lymphocytic leukemia (CLL)(Enjuanes et al., 2008; 19074885), non_Hodgkin lymphoma (Lan et al., 2009; 19414860), and B_cell acute lymphoblastic leukemia (B_ALL)(Carvalho et al., 2015; 26321572). CASP8 mutations have been observed in 8_9% of head and neck squamous cell carcinoma (HNSCC) (Li et al., 2014; 24816188, Stransky et al., 2011; 21798893, Kandoth et al., 2013; 24132290), 5% of colorectal (Kim et al., 2003; 12949717), 4% of cervical (The Cancer Genome Atlas Research Network, 2017; 28112728) and 3% of breast (Stephens et al., 2012; 22722201) carcinoma cases; mutations in HNSCC have been correlated with improved outcome (The Cancer Genome Atlas Network, 2015; 25631445). Loss of CASP8 expression is frequently observed in neuroblastoma, predominantly due to hypermethylation (Sanchez_Vega et al., 2013; 24149212), although deletions are also seen (Fulda et al., 2006; 17047064, Teitz et al., 2001; 11511973, Teitz et al., 2000; 10802708, Hoebeeck et al., 2009; 18819746). Loss of CASP8 expression in neuroblastoma has been implicated in promoting metastasis (Stupack et al., 2006; 16397500), recapitulated in a MYCN_driven mouse model of neuroblastoma (Teitz et al., 2013; 23536557), although there are conflicting reports regarding the prognostic impact of CASP8 (Asada et al., 2013; 23619990, Hoebeeck et al., 2009; 18819746, Fulda et al., 2006; 17047064). CASP8 hypermethylation and reduction of expression are also frequent in medulloblastoma (Zuzak et al., 2002; 11750844, Feierabend et al., 2014; 24162828, Gonzalez_Gomez et al., 2004; 15289853, Pingoud_Meier et al., 2003; 14695141), although impact on prognosis is unclear (Feierabend et al., 2014; 24162828, Pingoud_Meier et al., 2003; 14695141). Conversely, CASP8 overexpression has been noted in acute myeloid leukemia (AML) (Liu et al., 2012; 22722453), cervical cancer (Ekonomopoulou et al., 2011; 21436691), hepatocellular carcinoma (HCC) (Koschny et al., 2013; 24209510), non_small cell lung cancer (NSCLC) (Liao et al., 2015; 25866216), and myeloproliferative neoplasms (MPNs) (Malherbe et al., 2016; 27060176). The prognostic significance of CASP8 expression may depend on cancer type or context. Hypermethylation and/or reduced expression of CASP8 has been associated with poor prognosis in ovarian cancer (Hernandez et al., 2015; 28179987), prostate cancer (Rodr\u00edguez_Berriguete et al., 2015; 26507126), and B_ALL (Mata et al., 2010; 20232432), but has been reported to be a good prognostic marker in cervical squamous cell carcinoma (Yao et al., 2015; 26254281); moreover, CASP8 overexpression has been reported to be a poor prognostic factor in HCC (Koschny et al., 2013; 24209510) and NSCLC (Liao et al., 2015; 25866216). Germline SNPs in CASP8 have been correlated with prognosis and/or clinicopathological features in breast (Cai et al., 2017; 28915630, Kuhlmann et al., 2016; 27507139, Hein et al., 2017; 28757652), small cell lung (Jiang et al., 2016; 26988918), prostate (Tsuchiya et al., 2013; 23946871), and gastric (Gu et al., 2014; 24535941) cancers, renal cell carcinoma (De Martino et al., 2013; 23313206, Zhu et al., 2010; 20572163), and MYCN_amplified neuroblastoma (Rihani et al., 2014; 25502557). SNPs in CASP8 have also been correlated with survival in patients who have undergone an allogeneic stem cell transplantation following alemtuzumab_mediated T_cell depletion (Shaw et al., 2015; 25347010) and in patients with lung adenocarcinoma treated with platinum_based chemotherapy (Liu et al., 2017; 28278082). There are no targeted approaches to address alterations in CASP8. Inhibitors of caspase_8 have been used in cancer models (Terlizzi et al., 2015; 25917370, Liu et al., 2007; 18056196), and may be beneficial in certain contexts. However, this remains to be tested clinically.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS colorectal cancers (CRCs) make up 70_85% of CRC cases (Guastadisegni et al., 2010; 20627535, Pawlik et al., 2004; 15528785, Kocarnik et al., 2015; 26337942, Cancer Genome Atlas Network., 2012; 22810696, Jass, 2007; 17204026, Lal et al., 2015; 25949894). MSS colorectal cancers are molecularly heterogeneous, driven by diverse mechanisms such as extensive DNA methylation, oncogenic mutations in KRAS or BRAF, or chromosomal instability (Jass, 2007; 17204026). Multiple studies have shown that MSS CRCs have a worse prognosis than MSI_high tumors (Samowitz et al., 2001; 11535541, Elsaleh and Iacopetta, 2001; 12445368, Brueckl et al., 2003; 12820457, Guidoboni et al., 2001; 11438476, Gryfe et al., 2000; 10631274, Sinicrope et al., 2006; 16952542, Guastadisegni et al., 2010; 20627535, Laghi and Malesci, 2012; 22722556). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60). For patients with chemotherapy_refractory metastatic colorectal cancer, 92% of which were MSS or MSI_Intermediate, a Phase 3 trial reported no OS advantage from the combination of the PD_L1 inhibitor atezolizumab plus cobimetinib relative to regorafenib (8.9 vs. 8.5 months, HR=1.00); atezolizumab monotherapy similarly did not prolong OS (7.1 vs. 8.5 months, HR=1.19) (Ciardiello et al., 2018; ESMO Abstract LBA_004). MSI has not been found to be a predictive biomarker for combination chemotherapy regimens, including FOLFOX (Sinicrope et al., 2013; 24019539, Gavin et al., 2012; 23045248) and FOLFIRI (Bertagnolli et al., 2009; 19273709, Van Cutsem et al., 2009; 19451425). Patients with MSS CRC are more likely to benefit from postsurgical fluorouracil (FU)_based adjuvant therapy (Ribic et al., 2003; 12867608, Sargent et al., 2010; 20498393) but less likely to benefit from irinotecan chemotherapy (Fallik et al., 2003; 14522894).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "NRAS", "Include": "true", "Alterations": {"Alteration": {"Name": "wildtype", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "wildtype"}}, "Interpretation": "NRAS encodes a member of the RAS family of small GTPases that mediate transduction of growth signals. Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF_MAPK_ERK, PI3K, and other pathways (Pylayeva_Gupta et al., 2011; 21993244). No alterations in NRAS were identified in this case. The majority of colorectal cancers (CRCs) (91_98%) have been reported to lack NRAS mutations (Pentheroudakis et al., 2013; 23374602, Vaughn et al., 2011; 21305640, Janku et al., 2013; 23400451, De Roock et al., 2010; 20619739, Irahara et al., 2010; 20736745, Cancer Genome Atlas Network., 2012; 22810696, Schirripa et al., 2015; 24806288, Guo et al., 2018; 29666387). NRAS wild_type status has been reported to be associated with decreased frequency of metastasis (Guo et al., 2018; 29666387) and longer survival (Schirripa et al., 2015; 24806288, Cercek et al., 2017; 28446505) of patients with CRC. Lack of mutations in KRAS or NRAS is associated with clinical benefit of treatment with EGFR_targeting antibodies cetuximab (Van Cutsem et al., 2011; 21502544, Bokemeyer et al., 2011; 21228335, Karapetis et al., 2008; 18946061, De Roock et al., 2008; 17998284) or panitumumab (Douillard et al., 2014; 24718886, Douillard et al., 2012; 24024839, Amado et al., 2008; 18316791) for patients with CRC. Therefore, these agents are indicated to treat patients with CRC lacking such mutations (NCCN Guidelines v2.2021).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TP53", "Include": "true", "Alterations": {"Alteration": {"Name": "R342*", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R342*"}}, "Interpretation": "Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). TP53 mutations have been reported in up to 60% of colorectal cancer cases (Cancer Genome Atlas Network., 2012; 22810696, Goh et al., 1995; 7585578, Berg et al., 2010; 21103049, Han et al., 2013; 23700467, Peeters et al., 2013; 23325582, Malhotra et al., 2013; 23526092, Di Bartolomeo et al., 2013; 23821376). A study reported p53 expression in 49% of analyzed colorectal cancer cases (Wangefjord et al., 2013; 23337059). TP53 mutation has not been consistently demonstrated to be a significant independent prognostic marker in the context of CRC (Russo et al., 2005; 16172461). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633), or p53 gene therapy and immunotherapeutics such as SGT_53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628) and ALT_801 (Hajdenberg et al., 2012; ASCO Abstract e15010). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% (17/176) and SDs in 53.4% (94/176) of patients with solid tumors; the response rate was 21.1% (4/19) in patients with TP53 mutations versus 12.1% (4/33) in patients who were TP53 wild_type (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 31.9% (30/94, 3 CR) ORR and a 73.4% (69/94) DCR in patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 42.9% (9/21, 1 CR) ORR and a 76.2% (16/21) DCR in patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin in patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24.0% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71.4% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel in patients with solid tumors, 75.0% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Additionally, the combination of a CHK1 inhibitor and irinotecan reportedly reduced tumor growth and prolonged survival in a TP53_mutated, but not TP53_wild_type, breast cancer xenotransplant mouse model (Ma et al., 2012; 22446188). ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies (Kwok et al., 2016; 26563132, Boudny et al., 2019; 30975914); however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies (Dillon et al., 2017; 28062704, Middleton et al., 2018; 30127241). Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition. One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li_Fraumeni syndrome (ClinVar, Mar 2021)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "08", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "08"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Samstein et al., 2019; 30643254, Fabrizio et al., 2018; 30151257, Marabelle et al., 2020; 32919526). Elevated TMB has been reported in 8_25% of colorectal cancer (CRC) samples (George et al., 2016; ASCO Abstract 3587, Nagahashi et al., 2016; ASCO Abstract e15103)(Cancer Genome Atlas Network, 2012; 22810696, Stadler et al., 2016; 27022117). Multiple studies have reported that the majority (up to 90%) of hypermutant CRC cases exhibit high levels of microsatellite instability (MSI_H) and mismatch repair deficiency (MMR_D) (Cancer Genome Atlas Network, 2012; 22810696, Stadler et al., 2016; 27022117). Increased TMB is significantly associated with MSI_H and MMR_D, with studies reporting that 100% of MSI_H CRCs harbor elevated TMB and, conversely, that 100% of tumors with low TMB harbor intact MMR (George et al., 2016; ASCO Abstract 3587, Nagahashi et al., 2016; ASCO Abstract e15103)(Stadler et al., 2016; 27022117). A subset of CRCs that harbor increased TMB but not MSI_H are driven by mutations in POLE, which lead to an \u201cultramutated\u201d phenotype with especially high TMB (Cancer Genome Atlas Network, 2012; 22810696, Stadler et al., 2016; 27022117). Tumors with increased TMB harbor BRAF V600E mutations more frequently than those with low TMB (Cancer Genome Atlas Network, 2012; 22810696, Stadler et al., 2016; 27022117), whereas TMB_low tumors more frequently harbor mutations in TP53 and APC (Cancer Genome Atlas Network, 2012; 22810696). In a study for 61 patients with metastatic, microsatellite stable (MSS) CRC treated with best standard of care, plasma TMB scores \u226528 muts/Mb (approximately 14 muts/Mb as measured by this assay) were associated with reduced OS as compared with plasma TMB scores <28 muts/Mb (3.0 vs. 5.3 months, HR 0.76, p=0.007), whereas tissue TMB was not found to be prognostic in this population (Chen et al., 2020; 32379280, Loree et al., 2021; ASCO GI Abstract 61). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, higher TMB has been reported to be associated with increased ORR and OS from treatment with immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Higher TMB was found to be significantly associated with improved OS upon immune checkpoint inhibitor treatment for patients with 9 types of advanced tumors (Samstein et al., 2019; 30643254). Analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy, compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386). However, the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors found significant improvement in ORR for patients with TMB \u226510 Muts/Mb (based on this assay or others) compared to those with TMB <10 Muts/Mb, in a large cohort that included multiple tumor types; similar findings were observed in the KEYNOTE 028 and 012 trials (Marabelle et al., 2020; 32919526, Cristescu et al., 2018; 30309915). Together, these studies suggest that patients with TMB \u226510 Muts/Mb may derive clinical benefit from PD_1 or PD_L1 inhibitors. In CRC specifically, a retrospective analysis of immune checkpoint inhibitor efficacy reported significantly improved OS for patients with tumors harboring TMB \u22659.8 Muts/MB compared with those with tumors with TMB <9.8 Muts/Mb (~ equivalency <12 Muts/Mb as measured by this assay) (Samstein et al., 2019; 30643254). Another retrospective study reported that a TMB \u226512 Muts/Mb cutoff identifies >99% of MSI_High CRC cases but only 3% of MSS cases, indicating the utility of this cutoff for identification of patients with CRC likely to benefit from treatment with immune checkpoint inhibitors (Fabrizio et al., 2018; 30151257).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "KRAS", "Alteration": "G12D", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, KIT, PDGFRA, RET, VEGFRs, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. KRAS mutation may predict sensitivity to PLK1 inhibitors. Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant colorectal cancer; combination therapies may be more effective.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "G12D", "Title": "Dose_Escalation and Dose_Expansion of RMC_4630 and Cobimetinib in Relapsed/Refractory Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "SHP2, MEK", "Locations": "Seoul (Korea, Republic of), Oregon, California, Colorado, Arizona, Wisconsin, Illinois", "NCTID": "NCT03989115", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. KRAS mutation may predict sensitivity to PLK1 inhibitors. Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant colorectal cancer; combination therapies may be more effective.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "G12D", "Title": "Cobimetinib and HM95573 in Patients With Locally Advanced or Metastatic Solid Tumors", "StudyPhase": "PHASE 1", "Target": "MEK, RAFs", "Locations": "Hwasun (Korea, Republic of), Pusan (Korea, Republic of), Seongnam (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of)", "NCTID": "NCT03284502", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. KRAS mutation may predict sensitivity to PLK1 inhibitors. Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant colorectal cancer; combination therapies may be more effective.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "G12D", "Title": "Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma", "StudyPhase": "PHASE 1", "Target": "JAK2, JAK1, MEK", "Locations": "Singapore (Singapore)", "NCTID": "NCT04303403", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. KRAS mutation may predict sensitivity to PLK1 inhibitors. Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant colorectal cancer; combination therapies may be more effective.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "G12D", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. KRAS mutation may predict sensitivity to PLK1 inhibitors. Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant colorectal cancer; combination therapies may be more effective.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "G12D", "Title": "Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "BCL_W, BCL_XL, BCL2, MEK", "Locations": "Massachusetts", "NCTID": "NCT02079740", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. KRAS mutation may predict sensitivity to PLK1 inhibitors. Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant colorectal cancer; combination therapies may be more effective.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "G12D", "Title": "Study of the Safety and Pharmacokinetics of BGB_283 and PD_0325901 in Patients With Advanced or Refractory Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "RAFs, EGFR, MEK", "Locations": "Nedlands (Australia), Blacktown (Australia), Randwick (Australia), Melbourne (Australia), Texas", "NCTID": "NCT03905148", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. KRAS mutation may predict sensitivity to PLK1 inhibitors. Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant colorectal cancer; combination therapies may be more effective.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "G12D", "Title": "A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)", "StudyPhase": "PHASE 1", "Target": "KRAS, SOS1, MEK", "Locations": "Frankfurt am Main (Germany), K\u00f6ln (Germany), Utrecht (Netherlands), Rotterdam (Netherlands), Massachusetts, Tennessee, Texas, North Carolina", "NCTID": "NCT04111458", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. KRAS mutation may predict sensitivity to PLK1 inhibitors. Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant colorectal cancer; combination therapies may be more effective.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "G12D", "Title": "Safety and Efficacy of Pembrolizumab (MK_3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK_3475_651)", "StudyPhase": "PHASE 1", "Target": "PD_1, MEK", "Locations": "Washington, Edmonton (Canada), California, Colorado, Illinois, Montreal (Canada), Toronto (Canada), Pennsylvania, Connecticut", "NCTID": "NCT03374254", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. KRAS mutation may predict sensitivity to PLK1 inhibitors. Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant colorectal cancer; combination therapies may be more effective.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "G12D", "Title": "Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation", "StudyPhase": "PHASE 1/2", "Target": "PLK1, VEGFA", "Locations": "California, Arizona, Minnesota, Kansas, Arkansas, Virginia, Florida", "NCTID": "NCT03829410", "Note": "KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. KRAS mutation may predict sensitivity to PLK1 inhibitors. Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant colorectal cancer; combination therapies may be more effective.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "21993244", "FullCitation": "Pylayeva_Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244", "Include": "true"}, {"number": "1", "ReferenceId": "3310850", "FullCitation": "Kahn S, et al. Anticancer Res. () pmid: 3310850", "Include": "true"}, {"number": "2", "ReferenceId": "17150185", "FullCitation": "Akagi K, et al. Biochem. Biophys. Res. Commun. (2007) pmid: 17150185", "Include": "true"}, {"number": "3", "ReferenceId": "8955068", "FullCitation": "Bollag G, et al. J. Biol. Chem. (1996) pmid: 8955068", "Include": "true"}, {"number": "4", "ReferenceId": "20194776", "FullCitation": "Buhrman G, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20194776", "Include": "true"}, {"number": "5", "ReferenceId": "15367757", "FullCitation": "Sci. STKE (2004) pmid: 15367757", "Include": "true"}, {"number": "6", "ReferenceId": "16969076", "FullCitation": "Edkins S, et al. Cancer Biol. Ther. (2006) pmid: 16969076", "Include": "true"}, {"number": "7", "ReferenceId": "3043178", "FullCitation": "Feig LA, et al. Mol. Cell. Biol. (1988) pmid: 3043178", "Include": "true"}, {"number": "8", "ReferenceId": "20949621", "FullCitation": "Gremer L, et al. Hum. Mutat. (2011) pmid: 20949621", "Include": "true"}, {"number": "9", "ReferenceId": "20570890", "FullCitation": "Janakiraman M, et al. Cancer Res. (2010) pmid: 20570890", "Include": "true"}, {"number": "10", "ReferenceId": "27147599", "FullCitation": "Kim E, et al. Cancer Discov (2016) pmid: 27147599", "Include": "true"}, {"number": "11", "ReferenceId": "20838576", "FullCitation": "Lukman S, et al. PLoS Comput. Biol. (2010) pmid: 20838576", "Include": "true"}, {"number": "12", "ReferenceId": "21371307", "FullCitation": "Naguib A, et al. J Mol Signal (2011) pmid: 21371307", "Include": "true"}, {"number": "13", "ReferenceId": "22589270", "FullCitation": "Prior IA, et al. Cancer Res. (2012) pmid: 22589270", "Include": "true"}, {"number": "14", "ReferenceId": "1565661", "FullCitation": "Priv\u00e9 GG, et al. Proc. Natl. Acad. Sci. U.S.A. (1992) pmid: 1565661", "Include": "true"}, {"number": "15", "ReferenceId": "9219684", "FullCitation": "Scheffzek K, et al. Science (1997) pmid: 9219684", "Include": "true"}, {"number": "16", "ReferenceId": "19490892", "FullCitation": "Scholl C, et al. Cell (2009) pmid: 19490892", "Include": "true"}, {"number": "17", "ReferenceId": "20147967", "FullCitation": "Smith G, et al. Br. J. Cancer (2010) pmid: 20147967", "Include": "true"}, {"number": "18", "ReferenceId": "19075190", "FullCitation": "Tyner JW, et al. Blood (2009) pmid: 19075190", "Include": "true"}, {"number": "19", "ReferenceId": "2029511", "FullCitation": "Valencia A, et al. Biochemistry (1991) pmid: 2029511", "Include": "true"}, {"number": "20", "ReferenceId": "26854029", "FullCitation": "White Y, et al. Nat Commun (2016) pmid: 26854029", "Include": "true"}, {"number": "21", "ReferenceId": "8058307", "FullCitation": "Wiest JS, et al. Oncogene (1994) pmid: 8058307", "Include": "true"}, {"number": "22", "ReferenceId": "31289513", "FullCitation": "Angeles AKJ, et al. Oncol Lett (2019) pmid: 31289513", "Include": "true"}, {"number": "23", "ReferenceId": "24642870", "FullCitation": "Tong JH, et al. Cancer Biol. Ther. (2014) pmid: 24642870", "Include": "true"}, {"number": "24", "ReferenceId": "16618717", "FullCitation": "Li\u00e8vre A, et al. Cancer Res. (2006) pmid: 16618717", "Include": "true"}, {"number": "25", "ReferenceId": "21163703", "FullCitation": "De Roock W, et al. Lancet Oncol. (2011) pmid: 21163703", "Include": "true"}, {"number": "26", "ReferenceId": "25367198", "FullCitation": "Chen J, et al. BMC Cancer (2014) pmid: 25367198", "Include": "true"}, {"number": "27", "ReferenceId": "25929517", "FullCitation": "Li W, et al. BMC Cancer (2015) pmid: 25929517", "Include": "true"}, {"number": "28", "ReferenceId": "27977612", "FullCitation": "Hu J, et al. Medicine (Baltimore) (2016) pmid: 27977612", "Include": "true"}, {"number": "29", "ReferenceId": "28218784", "FullCitation": "Zekri J, et al. Genet. Mol. Res. (2017) pmid: 28218784", "Include": "true"}, {"number": "30", "ReferenceId": "29048416", "FullCitation": "Staudacher JJ, et al. Clin Transl Gastroenterol (2017) pmid: 29048416", "Include": "true"}, {"number": "31", "ReferenceId": "29705968", "FullCitation": "Wang Y, et al. Virchows Arch. (2018) pmid: 29705968", "Include": "true"}, {"number": "32", "ReferenceId": "29666387", "FullCitation": "Guo F, et al. Sci Rep (2018) pmid: 29666387", "Include": "true"}, {"number": "33", "ReferenceId": "28106826", "FullCitation": "M\u00e1rmol I, et al. Int J Mol Sci (2017) pmid: 28106826", "Include": "true"}, {"number": "34", "ReferenceId": "28858102", "FullCitation": "Kwak MS, et al. Medicine (Baltimore) (2017) pmid: 28858102", "Include": "true"}, {"number": "35", "ReferenceId": "6320174", "FullCitation": "Nakano H, et al. Proc. Natl. Acad. Sci. U.S.A. (1984) pmid: 6320174", "Include": "true"}, {"number": "36", "ReferenceId": "21523318", "FullCitation": "Yamaguchi T, et al. Int. J. Oncol. (2011) pmid: 21523318", "Include": "true"}, {"number": "37", "ReferenceId": "23438367", "FullCitation": "Watanabe M, et al. Cancer Sci. (2013) pmid: 23438367", "Include": "true"}, {"number": "38", "ReferenceId": "21245089", "FullCitation": "Gilmartin AG, et al. Clin. Cancer Res. (2011) pmid: 21245089", "Include": "true"}, {"number": "39", "ReferenceId": "19372556", "FullCitation": "Yeh JJ, et al. Mol. Cancer Ther. (2009) pmid: 19372556", "Include": "true"}, {"number": "40", "ReferenceId": "22805291", "FullCitation": "Infante JR, et al. Lancet Oncol. (2012) pmid: 22805291", "Include": "true"}, {"number": "41", "ReferenceId": "24947927", "FullCitation": "Zimmer L, et al. Clin. Cancer Res. (2014) pmid: 24947927", "Include": "true"}, {"number": "42", "ReferenceId": "20127139", "FullCitation": "Bennouna J, et al. Invest New Drugs (2011) pmid: 20127139", "Include": "true"}, {"number": "43", "ReferenceId": "23434733", "FullCitation": "Weekes CD, et al. Clin. Cancer Res. (2013) pmid: 23434733", "Include": "true"}, {"number": "44", "ReferenceId": "25199829", "FullCitation": "Lamba S, et al. Cell Rep (2014) pmid: 25199829", "Include": "true"}, {"number": "45", "ReferenceId": "24685132", "FullCitation": "Sun C, et al. Cell Rep (2014) pmid: 24685132", "Include": "true"}, {"number": "46", "ReferenceId": "31068384", "FullCitation": "Lu H, et al. Mol Cancer Ther (2019) pmid: 31068384", "Include": "true"}, {"number": "47", "ReferenceId": "29808006", "FullCitation": "Mainardi S, et al. Nat Med (2018) pmid: 29808006", "Include": "true"}, {"number": "48", "ReferenceId": "19490893", "FullCitation": "Luo J, et al. Cell (2009) pmid: 19490893", "Include": "true"}, {"number": "49", "ReferenceId": "9628872", "FullCitation": "Strong JE, et al. EMBO J. (1998) pmid: 9628872", "Include": "true"}, {"number": "50", "ReferenceId": "9812900", "FullCitation": "Coffey MC, et al. Science (1998) pmid: 9812900", "Include": "true"}, {"number": "51", "ReferenceId": "25019061", "FullCitation": "Gong J, et al. Front Oncol (2014) pmid: 25019061", "Include": "true"}, {"number": "52", "ReferenceId": "18253152", "FullCitation": "Forsyth P, et al. Mol. Ther. (2008) pmid: 18253152", "Include": "true"}, {"number": "53", "ReferenceId": "18981012", "FullCitation": "Vidal L, et al. Clin. Cancer Res. (2008) pmid: 18981012", "Include": "true"}, {"number": "54", "ReferenceId": "19572105", "FullCitation": "Gollamudi R, et al. Invest New Drugs (2010) pmid: 19572105", "Include": "true"}, {"number": "55", "ReferenceId": "20484020", "FullCitation": "Harrington KJ, et al. Clin. Cancer Res. (2010) pmid: 20484020", "Include": "true"}, {"number": "56", "ReferenceId": "20926400", "FullCitation": "Comins C, et al. Clin. Cancer Res. (2010) pmid: 20926400", "Include": "true"}, {"number": "57", "ReferenceId": "21106728", "FullCitation": "Lolkema MP, et al. Clin. Cancer Res. (2011) pmid: 21106728", "Include": "true"}, {"number": "58", "ReferenceId": "22871663", "FullCitation": "Galanis E, et al. Mol. Ther. (2012) pmid: 22871663", "Include": "true"}, {"number": "59", "ReferenceId": "22316603", "FullCitation": "Karapanagiotou EM, et al. Clin. Cancer Res. (2012) pmid: 22316603", "Include": "true"}, {"number": "60", "ReferenceId": "22886613", "FullCitation": "Morris DG, et al. Invest New Drugs (2013) pmid: 22886613", "Include": "true"}, {"number": "61", "ReferenceId": "21502544", "FullCitation": "Van Cutsem E, et al. J. Clin. Oncol. (2011) pmid: 21502544", "Include": "true"}, {"number": "62", "ReferenceId": "21228335", "FullCitation": "Bokemeyer C, et al. Ann. Oncol. (2011) pmid: 21228335", "Include": "true"}, {"number": "63", "ReferenceId": "18946061", "FullCitation": "Karapetis CS, et al. N. Engl. J. Med. (2008) pmid: 18946061", "Include": "true"}, {"number": "64", "ReferenceId": "17998284", "FullCitation": "De Roock W, et al. Ann. Oncol. (2008) pmid: 17998284", "Include": "true"}, {"number": "65", "ReferenceId": "24718886", "FullCitation": "Douillard JY, et al. Ann. Oncol. (2014) pmid: 24718886", "Include": "true"}, {"number": "66", "ReferenceId": "24024839", "FullCitation": "Douillard JY, et al. N. Engl. J. Med. (2013) pmid: 24024839", "Include": "true"}, {"number": "67", "ReferenceId": "18316791", "FullCitation": "Amado RG, et al. J. Clin. Oncol. (2008) pmid: 18316791", "Include": "true"}, {"number": "68", "ReferenceId": "26885855", "FullCitation": "Galluzzi L, et al. Immunity (2016) pmid: 26885855", "Include": "true"}, {"number": "69", "ReferenceId": "28462525", "FullCitation": "Tummers B, et al. Immunol. Rev. (2017) pmid: 28462525", "Include": "true"}, {"number": "70", "ReferenceId": "23070000", "FullCitation": "Crowder RN, et al. Exp. Oncol. (2012) pmid: 23070000", "Include": "true"}, {"number": "71", "ReferenceId": "21801448", "FullCitation": "Liu J, et al. Mol. Cancer (2011) pmid: 21801448", "Include": "true"}, {"number": "72", "ReferenceId": "24467204", "FullCitation": "Graf RP, et al. Curr. Mol. Med. (2014) pmid: 24467204", "Include": "true"}, {"number": "73", "ReferenceId": "19383910", "FullCitation": "Barbero S, et al. Cancer Res. (2009) pmid: 19383910", "Include": "true"}, {"number": "74", "ReferenceId": "25446254", "FullCitation": "Zhang L, et al. Cell. Signal. (2015) pmid: 25446254", "Include": "true"}, {"number": "75", "ReferenceId": "15746428", "FullCitation": "Su H, et al. Science (2005) pmid: 15746428", "Include": "true"}, {"number": "76", "ReferenceId": "28212752", "FullCitation": "Henry CM, et al. Mol. Cell (2017) pmid: 28212752", "Include": "true"}, {"number": "77", "ReferenceId": "21975294", "FullCitation": "Kober AM, et al. Cell Death Dis (2011) pmid: 21975294", "Include": "true"}, {"number": "78", "ReferenceId": "21152872", "FullCitation": "Sun BK, et al. Oncol. Rep. (2011) pmid: 21152872", "Include": "true"}, {"number": "79", "ReferenceId": "15705878", "FullCitation": "Soung YH, et al. Cancer Res. (2005) pmid: 15705878", "Include": "true"}, {"number": "80", "ReferenceId": "15531912", "FullCitation": "Soung YH, et al. Oncogene (2005) pmid: 15531912", "Include": "true"}, {"number": "81", "ReferenceId": "9271594", "FullCitation": "Mandruzzato S, et al. J. Exp. Med. (1997) pmid: 9271594", "Include": "true"}, {"number": "82", "ReferenceId": "12949717", "FullCitation": "Kim HS, et al. Gastroenterology (2003) pmid: 12949717", "Include": "true"}, {"number": "83", "ReferenceId": "24816188", "FullCitation": "Li C, et al. Mol Oncol (2014) pmid: 24816188", "Include": "true"}, {"number": "84", "ReferenceId": "23659359", "FullCitation": "Ando M, et al. Cancer Sci. (2013) pmid: 23659359", "Include": "true"}, {"number": "85", "ReferenceId": "23479148", "FullCitation": "Zhang YJ, et al. Genet. Mol. Res. (2013) pmid: 23479148", "Include": "true"}, {"number": "86", "ReferenceId": "23170140", "FullCitation": "Chen D, et al. Exp Ther Med (2012) pmid: 23170140", "Include": "true"}, {"number": "87", "ReferenceId": "28915630", "FullCitation": "Cai J, et al. Oncotarget (2017) pmid: 28915630", "Include": "true"}, {"number": "88", "ReferenceId": "28674227", "FullCitation": "Zhang Y, et al. J. Genet. (2017) pmid: 28674227", "Include": "true"}, {"number": "89", "ReferenceId": "25553350", "FullCitation": "Ji GH, et al. Cell. Mol. Biol. (Noisy_le_grand) (2014) pmid: 25553350", "Include": "true"}, {"number": "90", "ReferenceId": "26740556", "FullCitation": "Stacey SN, et al. Hum. Mol. Genet. (2016) pmid: 26740556", "Include": "true"}, {"number": "91", "ReferenceId": "23946871", "FullCitation": "Tsuchiya N, et al. Genes Cancer (2013) pmid: 23946871", "Include": "true"}, {"number": "92", "ReferenceId": "20978178", "FullCitation": "Engel C, et al. Cancer Epidemiol. Biomarkers Prev. (2010) pmid: 20978178", "Include": "true"}, {"number": "93", "ReferenceId": "20502973", "FullCitation": "Latif A, et al. Fam. Cancer (2010) pmid: 20502973", "Include": "true"}, {"number": "94", "ReferenceId": "21714991", "FullCitation": "Ma X, et al. Gynecol. Oncol. (2011) pmid: 21714991", "Include": "true"}, {"number": "95", "ReferenceId": "23313206", "FullCitation": "de Martino M, et al. J. Urol. (2013) pmid: 23313206", "Include": "true"}, {"number": "96", "ReferenceId": "20572163", "FullCitation": "Zhu J, et al. Mol. Carcinog. (2010) pmid: 20572163", "Include": "true"}, {"number": "97", "ReferenceId": "22513478", "FullCitation": "Zhang F, et al. Mutagenesis (2012) pmid: 22513478", "Include": "true"}, {"number": "98", "ReferenceId": "23921907", "FullCitation": "Hyland PL, et al. Int. J. Cancer (2014) pmid: 23921907", "Include": "true"}, {"number": "99", "ReferenceId": "25731870", "FullCitation": "Mocellin S, et al. Gut (2015) pmid: 25731870", "Include": "true"}, {"number": "100", "ReferenceId": "28542283", "FullCitation": "Zhao XK, et al. PLoS ONE (2017) pmid: 28542283", "Include": "true"}, {"number": "101", "ReferenceId": "26635288", "FullCitation": "Hyland PL, et al. Int J Epidemiol (2016) pmid: 26635288", "Include": "true"}, {"number": "102", "ReferenceId": "24464182", "FullCitation": "Yin J, et al. Mol. Biol. Rep. (2014) pmid: 24464182", "Include": "true"}, {"number": "103", "ReferenceId": "26458812", "FullCitation": "Chattopadhyay K, et al. BMC Cancer (2015) pmid: 26458812", "Include": "true"}, {"number": "104", "ReferenceId": "19276244", "FullCitation": "Wang M, et al. Clin. Cancer Res. (2009) pmid: 19276244", "Include": "true"}, {"number": "105", "ReferenceId": "25855136", "FullCitation": "Stacey SN, et al. Nat Commun (2015) pmid: 25855136", "Include": "true"}, {"number": "106", "ReferenceId": "19074885", "FullCitation": "Enjuanes A, et al. Cancer Res. (2008) pmid: 19074885", "Include": "true"}, {"number": "107", "ReferenceId": "19414860", "FullCitation": "Lan Q, et al. Blood (2009) pmid: 19414860", "Include": "true"}, {"number": "108", "ReferenceId": "26321572", "FullCitation": "Carvalho DC, et al. Leuk. Res. (2015) pmid: 26321572", "Include": "true"}, {"number": "109", "ReferenceId": "21798893", "FullCitation": "Stransky N, et al. Science (2011) pmid: 21798893", "Include": "true"}, {"number": "110", "ReferenceId": "24132290", "FullCitation": "Kandoth C, et al. Nature (2013) pmid: 24132290", "Include": "true"}, {"number": "111", "ReferenceId": "28112728", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2017) pmid: 28112728", "Include": "true"}, {"number": "112", "ReferenceId": "22722201", "FullCitation": "Stephens PJ, et al. Nature (2012) pmid: 22722201", "Include": "true"}, {"number": "113", "ReferenceId": "25631445", "FullCitation": "Nature (2015) pmid: 25631445", "Include": "true"}, {"number": "114", "ReferenceId": "24149212", "FullCitation": "S\u00e1nchez_Vega F, et al. Epigenetics (2013) pmid: 24149212", "Include": "true"}, {"number": "115", "ReferenceId": "17047064", "FullCitation": "Fulda S, et al. Cancer Res. (2006) pmid: 17047064", "Include": "true"}, {"number": "116", "ReferenceId": "11511973", "FullCitation": "Teitz T, et al. J. Mol. Med. (2001) pmid: 11511973", "Include": "true"}, {"number": "117", "ReferenceId": "10802708", "FullCitation": "Teitz T, et al. Nat. Med. (2000) pmid: 10802708", "Include": "true"}, {"number": "118", "ReferenceId": "18819746", "FullCitation": "Hoebeeck J, et al. Cancer Lett. (2009) pmid: 18819746", "Include": "true"}, {"number": "119", "ReferenceId": "16397500", "FullCitation": "Stupack DG, et al. Nature (2006) pmid: 16397500", "Include": "true"}, {"number": "120", "ReferenceId": "23536557", "FullCitation": "Teitz T, et al. Cancer Res. (2013) pmid: 23536557", "Include": "true"}, {"number": "121", "ReferenceId": "23619990", "FullCitation": "Asada K, et al. Jpn. J. Clin. Oncol. (2013) pmid: 23619990", "Include": "true"}, {"number": "122", "ReferenceId": "11750844", "FullCitation": "Zuzak TJ, et al. Eur. J. Cancer (2002) pmid: 11750844", "Include": "true"}, {"number": "123", "ReferenceId": "24162828", "FullCitation": "Feierabend D, et al. J. Neurooncol. (2014) pmid: 24162828", "Include": "true"}, {"number": "124", "ReferenceId": "15289853", "FullCitation": "Gonzalez_Gomez P, et al. Oncol. Rep. (2004) pmid: 15289853", "Include": "true"}, {"number": "125", "ReferenceId": "14695141", "FullCitation": "Pingoud_Meier C, et al. Clin. Cancer Res. (2003) pmid: 14695141", "Include": "true"}, {"number": "126", "ReferenceId": "22722453", "FullCitation": "Liu J, et al. Onkologie (2012) pmid: 22722453", "Include": "true"}, {"number": "127", "ReferenceId": "21436691", "FullCitation": "Ekonomopoulou MT, et al. Int. J. Gynecol. Cancer (2011) pmid: 21436691", "Include": "true"}, {"number": "128", "ReferenceId": "24209510", "FullCitation": "Koschny R, et al. BMC Cancer (2013) pmid: 24209510", "Include": "true"}, {"number": "129", "ReferenceId": "25866216", "FullCitation": "Liao Y, et al. Neoplasma (2015) pmid: 25866216", "Include": "true"}, {"number": "130", "ReferenceId": "27060176", "FullCitation": "Malherbe JA, et al. J. Clin. Pathol. (2016) pmid: 27060176", "Include": "true"}, {"number": "131", "ReferenceId": "28179987", "FullCitation": "Hernandez L, et al. Cell Death Discov (2015) pmid: 28179987", "Include": "true"}, {"number": "132", "ReferenceId": "26507126", "FullCitation": "Rodr\u00edguez_Berriguete G, et al. BMC Cancer (2015) pmid: 26507126", "Include": "true"}, {"number": "133", "ReferenceId": "20232432", "FullCitation": "Mata JF, et al. Pediatr Blood Cancer (2010) pmid: 20232432", "Include": "true"}, {"number": "134", "ReferenceId": "26254281", "FullCitation": "Yao Q, et al. J. Clin. Pathol. (2016) pmid: 26254281", "Include": "true"}, {"number": "135", "ReferenceId": "27507139", "FullCitation": "Kuhlmann JD, et al. BMC Cancer (2016) pmid: 27507139", "Include": "true"}, {"number": "136", "ReferenceId": "28757652", "FullCitation": "Hein A, et al. Geburtshilfe Frauenheilkd (2017) pmid: 28757652", "Include": "true"}, {"number": "137", "ReferenceId": "26988918", "FullCitation": "Jiang W, et al. Oncotarget (2016) pmid: 26988918", "Include": "true"}, {"number": "138", "ReferenceId": "24535941", "FullCitation": "Gu D, et al. Environ. Mol. Mutagen. (2014) pmid: 24535941", "Include": "true"}, {"number": "139", "ReferenceId": "25502557", "FullCitation": "Rihani A, et al. PLoS ONE (2014) pmid: 25502557", "Include": "true"}, {"number": "140", "ReferenceId": "25347010", "FullCitation": "Shaw BE, et al. Bone Marrow Transplant. (2015) pmid: 25347010", "Include": "true"}, {"number": "141", "ReferenceId": "28278082", "FullCitation": "Liu D, et al. Cancer Biol. Ther. (2017) pmid: 28278082", "Include": "true"}, {"number": "142", "ReferenceId": "25917370", "FullCitation": "Terlizzi M, et al. Br. J. Pharmacol. (2015) pmid: 25917370", "Include": "true"}, {"number": "143", "ReferenceId": "18056196", "FullCitation": "Liu C, et al. Clin. Cancer Res. (2007) pmid: 18056196", "Include": "true"}, {"number": "144", "ReferenceId": "15473860", "FullCitation": "Logan CY, et al. Annu. Rev. Cell Dev. Biol. (2004) pmid: 15473860", "Include": "true"}, {"number": "145", "ReferenceId": "11707392", "FullCitation": "Eklof Spink K, et al. EMBO J. (2001) pmid: 11707392", "Include": "true"}, {"number": "146", "ReferenceId": "16753179", "FullCitation": "Liu J, et al. J. Mol. Biol. (2006) pmid: 16753179", "Include": "true"}, {"number": "147", "ReferenceId": "20144988", "FullCitation": "Dikovskaya D, et al. J. Cell. Sci. (2010) pmid: 20144988", "Include": "true"}, {"number": "148", "ReferenceId": "17410430", "FullCitation": "Murphy SJ, et al. Dig. Dis. Sci. (2007) pmid: 17410430", "Include": "true"}, {"number": "149", "ReferenceId": "15459959", "FullCitation": "Aretz S, et al. Hum. Mutat. (2004) pmid: 15459959", "Include": "true"}, {"number": "150", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "151", "ReferenceId": "21455986", "FullCitation": "Fu Y, et al. Int. J. Cancer (2011) pmid: 21455986", "Include": "true"}, {"number": "152", "ReferenceId": "19110823", "FullCitation": "Quyn AJ, et al. Surgeon (2008) pmid: 19110823", "Include": "true"}, {"number": "153", "ReferenceId": "30635339", "FullCitation": "Luke JJ, et al. Clin Cancer Res (2019) pmid: 30635339", "Include": "true"}, {"number": "154", "ReferenceId": "20348907", "FullCitation": "Zhang L, et al. Nature (2010) pmid: 20348907", "Include": "true"}, {"number": "155", "ReferenceId": "19026633", "FullCitation": "Lu W, et al. Eur. J. Pharmacol. (2009) pmid: 19026633", "Include": "true"}, {"number": "156", "ReferenceId": "18281498", "FullCitation": "Tuynman JB, et al. Cancer Res. (2008) pmid: 18281498", "Include": "true"}, {"number": "157", "ReferenceId": "23539443", "FullCitation": "Lau T, et al. Cancer Res. (2013) pmid: 23539443", "Include": "true"}, {"number": "158", "ReferenceId": "23159591", "FullCitation": "Kerr SE, et al. J Mol Diagn (2013) pmid: 23159591", "Include": "true"}, {"number": "159", "ReferenceId": "21090969", "FullCitation": "Annu Rev Pathol (2011) pmid: 21090969", "Include": "true"}, {"number": "160", "ReferenceId": "18844223", "FullCitation": "Kastritis E, et al. Int. J. Cancer (2009) pmid: 18844223", "Include": "true"}, {"number": "161", "ReferenceId": "19822006", "FullCitation": "Half E, et al. Orphanet J Rare Dis (2009) pmid: 19822006", "Include": "true"}, {"number": "162", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "163", "ReferenceId": "18410249", "FullCitation": "Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249", "Include": "true"}, {"number": "164", "ReferenceId": "12826609", "FullCitation": "Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609", "Include": "true"}, {"number": "165", "ReferenceId": "20978130", "FullCitation": "Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130", "Include": "true"}, {"number": "166", "ReferenceId": "28472496", "FullCitation": "Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496", "Include": "true"}, {"number": "167", "ReferenceId": "17690113", "FullCitation": "Yamada H, et al. Carcinogenesis (2007) pmid: 17690113", "Include": "true"}, {"number": "168", "ReferenceId": "7585578", "FullCitation": "Goh HS, et al. Cancer Res. (1995) pmid: 7585578", "Include": "true"}, {"number": "169", "ReferenceId": "21103049", "FullCitation": "Berg M, et al. PLoS ONE (2010) pmid: 21103049", "Include": "true"}, {"number": "170", "ReferenceId": "23700467", "FullCitation": "Han SW, et al. PLoS ONE (2013) pmid: 23700467", "Include": "true"}, {"number": "171", "ReferenceId": "23325582", "FullCitation": "Peeters M, et al. Clin. Cancer Res. (2013) pmid: 23325582", "Include": "true"}, {"number": "172", "ReferenceId": "23526092", "FullCitation": "Malhotra P, et al. Tumour Biol. (2013) pmid: 23526092", "Include": "true"}, {"number": "173", "ReferenceId": "23821376", "FullCitation": "Di Bartolomeo M, et al. Target Oncol (2014) pmid: 23821376", "Include": "true"}, {"number": "174", "ReferenceId": "23337059", "FullCitation": "Wangefjord S, et al. Diagn Pathol (2013) pmid: 23337059", "Include": "true"}, {"number": "175", "ReferenceId": "16172461", "FullCitation": "Russo A, et al. J. Clin. Oncol. (2005) pmid: 16172461", "Include": "true"}, {"number": "176", "ReferenceId": "20107315", "FullCitation": "Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315", "Include": "true"}, {"number": "177", "ReferenceId": "21799033", "FullCitation": "Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033", "Include": "true"}, {"number": "178", "ReferenceId": "21389100", "FullCitation": "Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100", "Include": "true"}, {"number": "179", "ReferenceId": "25504633", "FullCitation": "Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633", "Include": "true"}, {"number": "180", "ReferenceId": "12489850", "FullCitation": "Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850", "Include": "true"}, {"number": "181", "ReferenceId": "11713371", "FullCitation": "Xu L, et al. Mol. Med. (2001) pmid: 11713371", "Include": "true"}, {"number": "182", "ReferenceId": "23470564", "FullCitation": "Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564", "Include": "true"}, {"number": "183", "ReferenceId": "25240597", "FullCitation": "Kim SS, et al. Nanomedicine (2015) pmid: 25240597", "Include": "true"}, {"number": "184", "ReferenceId": "27357628", "FullCitation": "Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628", "Include": "true"}, {"number": "185", "ReferenceId": "27601554", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554", "Include": "true"}, {"number": "186", "ReferenceId": "27998224", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224", "Include": "true"}, {"number": "187", "ReferenceId": "31315834", "FullCitation": "Lee J, et al. Cancer Discov (2019) pmid: 31315834", "Include": "true"}, {"number": "188", "ReferenceId": "29535125", "FullCitation": "M\u00e9ndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125", "Include": "true"}, {"number": "189", "ReferenceId": "22446188", "FullCitation": "Ma CX, et al. J. Clin. Invest. (2012) pmid: 22446188", "Include": "true"}, {"number": "190", "ReferenceId": "26563132", "FullCitation": "Kwok M, et al. Blood (2016) pmid: 26563132", "Include": "true"}, {"number": "191", "ReferenceId": "30975914", "FullCitation": "Boudny M, et al. Haematologica (2019) pmid: 30975914", "Include": "true"}, {"number": "192", "ReferenceId": "28062704", "FullCitation": "Dillon MT, et al. Mol. Cancer Ther. (2017) pmid: 28062704", "Include": "true"}, {"number": "193", "ReferenceId": "30127241", "FullCitation": "Middleton FK, et al. Cancers (Basel) (2018) pmid: 30127241", "Include": "true"}, {"number": "194", "ReferenceId": "29165669", "FullCitation": "Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669", "Include": "true"}, {"number": "195", "ReferenceId": "26014290", "FullCitation": "Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290", "Include": "true"}, {"number": "196", "ReferenceId": "23355100", "FullCitation": "Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100", "Include": "true"}, {"number": "197", "ReferenceId": "11219776", "FullCitation": "Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776", "Include": "true"}, {"number": "198", "ReferenceId": "9006316", "FullCitation": "Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316", "Include": "true"}, {"number": "199", "ReferenceId": "19204208", "FullCitation": "Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208", "Include": "true"}, {"number": "200", "ReferenceId": "12672316", "FullCitation": "Lalloo F, et al. Lancet (2003) pmid: 12672316", "Include": "true"}, {"number": "201", "ReferenceId": "31050713", "FullCitation": "Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713", "Include": "true"}, {"number": "202", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "203", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "204", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "205", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "206", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "207", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "208", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "209", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "210", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "211", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "212", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "213", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "214", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "215", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "216", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "217", "ReferenceId": "20627535", "FullCitation": "Guastadisegni C, et al. Eur. J. Cancer (2010) pmid: 20627535", "Include": "true"}, {"number": "218", "ReferenceId": "17204026", "FullCitation": "Histopathology (2007) pmid: 17204026", "Include": "true"}, {"number": "219", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "220", "ReferenceId": "11535541", "FullCitation": "Samowitz WS, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11535541", "Include": "true"}, {"number": "221", "ReferenceId": "12445368", "FullCitation": "Elsaleh H, et al. Clin Colorectal Cancer (2001) pmid: 12445368", "Include": "true"}, {"number": "222", "ReferenceId": "12820457", "FullCitation": "Brueckl WM, et al. Anticancer Res. () pmid: 12820457", "Include": "true"}, {"number": "223", "ReferenceId": "11438476", "FullCitation": "Guidoboni M, et al. Am. J. Pathol. (2001) pmid: 11438476", "Include": "true"}, {"number": "224", "ReferenceId": "10631274", "FullCitation": "Gryfe R, et al. N. Engl. J. Med. (2000) pmid: 10631274", "Include": "true"}, {"number": "225", "ReferenceId": "16952542", "FullCitation": "Sinicrope FA, et al. Gastroenterology (2006) pmid: 16952542", "Include": "true"}, {"number": "226", "ReferenceId": "22722556", "FullCitation": "Laghi L, et al. Dig Dis (2012) pmid: 22722556", "Include": "true"}, {"number": "227", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "228", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "229", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "230", "ReferenceId": "24019539", "FullCitation": "Sinicrope FA, et al. J. Clin. Oncol. (2013) pmid: 24019539", "Include": "true"}, {"number": "231", "ReferenceId": "23045248", "FullCitation": "Gavin PG, et al. Clin. Cancer Res. (2012) pmid: 23045248", "Include": "true"}, {"number": "232", "ReferenceId": "19273709", "FullCitation": "Bertagnolli MM, et al. J. Clin. Oncol. (2009) pmid: 19273709", "Include": "true"}, {"number": "233", "ReferenceId": "19451425", "FullCitation": "Van Cutsem E, et al. J. Clin. Oncol. (2009) pmid: 19451425", "Include": "true"}, {"number": "234", "ReferenceId": "12867608", "FullCitation": "Ribic CM, et al. N. Engl. J. Med. (2003) pmid: 12867608", "Include": "true"}, {"number": "235", "ReferenceId": "20498393", "FullCitation": "Sargent DJ, et al. J. Clin. Oncol. (2010) pmid: 20498393", "Include": "true"}, {"number": "236", "ReferenceId": "14522894", "FullCitation": "Fallik D, et al. Cancer Res. (2003) pmid: 14522894", "Include": "true"}, {"number": "237", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "238", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "239", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "240", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "241", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "242", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "243", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "244", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "245", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "246", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "247", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "248", "ReferenceId": "30151257", "FullCitation": "Fabrizio DA, et al. J Gastrointest Oncol (2018) pmid: 30151257", "Include": "true"}, {"number": "249", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "250", "ReferenceId": "27022117", "FullCitation": "Stadler ZK, et al. J. Clin. Oncol. (2016) pmid: 27022117", "Include": "true"}, {"number": "251", "ReferenceId": "32379280", "FullCitation": "Chen EX, et al. JAMA Oncol (2020) pmid: 32379280", "Include": "true"}, {"number": "252", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "253", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "254", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "255", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "256", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "257", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "258", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "259", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "260", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "261", "ReferenceId": "23374602", "FullCitation": "Pentheroudakis G, et al. BMC Cancer (2013) pmid: 23374602", "Include": "true"}, {"number": "262", "ReferenceId": "21305640", "FullCitation": "Vaughn CP, et al. Genes Chromosomes Cancer (2011) pmid: 21305640", "Include": "true"}, {"number": "263", "ReferenceId": "23400451", "FullCitation": "Janku F, et al. Target Oncol (2013) pmid: 23400451", "Include": "true"}, {"number": "264", "ReferenceId": "20619739", "FullCitation": "De Roock W, et al. Lancet Oncol. (2010) pmid: 20619739", "Include": "true"}, {"number": "265", "ReferenceId": "20736745", "FullCitation": "Irahara N, et al. Diagn. Mol. Pathol. (2010) pmid: 20736745", "Include": "true"}, {"number": "266", "ReferenceId": "24806288", "FullCitation": "Schirripa M, et al. Int. J. Cancer (2015) pmid: 24806288", "Include": "true"}, {"number": "267", "ReferenceId": "28446505", "FullCitation": "Cercek A, et al. Clin. Cancer Res. (2017) pmid: 28446505", "Include": "true"}, {"number": "268", "ReferenceId": "24739896", "FullCitation": "Price TJ, et al. Lancet Oncol. (2014) pmid: 24739896", "Include": "true"}, {"number": "269", "ReferenceId": "32526634", "FullCitation": "Sakai D, et al. Eur J Cancer (2020) pmid: 32526634", "Include": "true"}, {"number": "270", "ReferenceId": "18003960", "FullCitation": "Jonker DJ, et al. N. Engl. J. Med. (2007) pmid: 18003960", "Include": "true"}, {"number": "271", "ReferenceId": "15269313", "FullCitation": "Cunningham D, et al. N. Engl. J. Med. (2004) pmid: 15269313", "Include": "true"}, {"number": "272", "ReferenceId": "29470838", "FullCitation": "Moiseyenko VM, et al. Clin Drug Investig (2018) pmid: 29470838", "Include": "true"}, {"number": "273", "ReferenceId": "17470858", "FullCitation": "Van Cutsem E, et al. J. Clin. Oncol. (2007) pmid: 17470858", "Include": "true"}, {"number": "274", "ReferenceId": "31268481", "FullCitation": "Pietrantonio F, et al. JAMA Oncol (2019) pmid: 31268481", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2021_09_14 15:25:36", "OpName": "Naomi Lynn Ferguson, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Naomi Lynn Ferguson, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "934x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "8 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "2 pca_score"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "COLON", "disease_ontology": "Colon adenocarcinoma (CRC)", "flowcell_analysis": "2000017525", "gender": "male", "pathology_diagnosis": "CRC", "percent_tumor_nuclei": "30", "pipeline_version": "v3.7.0", "purity_assessment": "43.7", "specimen": "ORD_1182592_01*US1143571.01", "study": "CLINICAL_F1CDx", "test_request": "ORD_1182592_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Lung", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX1", "mean_exon_depth": "940.53", "name": "SQ_US1143571.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.4711", "cds_effect": "3044C>T", "depth": "917", "equivocal": "false", "functional_effect": "missense", "gene": "PTPRO", "percent_reads": "47.11", "position": "chr12:15733677", "protein_effect": "P1015L", "status": "unknown", "strand": "+", "transcript": "NM_030667", "dna_evidence": {"sample": "SQ_US1143571.01_1"}}, {"allele_fraction": "0.4646", "cds_effect": "1024C>T", "depth": "678", "equivocal": "false", "functional_effect": "nonsense", "gene": "TP53", "percent_reads": "46.46", "position": "chr17:7574003", "protein_effect": "R342*", "status": "known", "strand": "_", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1143571.01_1"}}, {"allele_fraction": "0.4075", "cds_effect": "4793A>T", "depth": "535", "equivocal": "false", "functional_effect": "missense", "gene": "NOTCH3", "percent_reads": "40.75", "position": "chr19:15281580", "protein_effect": "D1598V", "status": "unknown", "strand": "_", "transcript": "NM_000435", "dna_evidence": {"sample": "SQ_US1143571.01_1"}}, {"allele_fraction": "0.3602", "cds_effect": "4135G>T", "depth": "769", "equivocal": "false", "functional_effect": "nonsense", "gene": "APC", "percent_reads": "36.02", "position": "chr5:112175426", "protein_effect": "E1379*", "status": "known", "strand": "+", "transcript": "NM_000038", "dna_evidence": {"sample": "SQ_US1143571.01_1"}}, {"allele_fraction": "0.3564", "cds_effect": "268A>G", "depth": "463", "equivocal": "false", "functional_effect": "missense", "gene": "ARID1A", "percent_reads": "35.64", "position": "chr1:27023162", "protein_effect": "S90G", "status": "unknown", "strand": "+", "transcript": "NM_006015", "dna_evidence": {"sample": "SQ_US1143571.01_1"}}, {"allele_fraction": "0.1339", "cds_effect": "3827C>A", "depth": "866", "equivocal": "false", "functional_effect": "nonsense", "gene": "APC", "percent_reads": "13.39", "position": "chr5:112175118", "protein_effect": "S1276*", "status": "known", "strand": "+", "transcript": "NM_000038", "dna_evidence": {"sample": "SQ_US1143571.01_1"}}, {"allele_fraction": "0.5537", "cds_effect": "188A>G", "depth": "800", "equivocal": "false", "functional_effect": "missense", "gene": "TGFBR2", "percent_reads": "55.37", "position": "chr3:30686332", "protein_effect": "N63S", "status": "unknown", "strand": "+", "transcript": "NM_003242", "dna_evidence": {"sample": "SQ_US1143571.01_1"}}, {"allele_fraction": "0.2377", "cds_effect": "2686A>G", "depth": "749", "equivocal": "false", "functional_effect": "missense", "gene": "BRIP1", "percent_reads": "23.77", "position": "chr17:59763416", "protein_effect": "I896V", "status": "unknown", "strand": "_", "transcript": "NM_032043", "dna_evidence": {"sample": "SQ_US1143571.01_1"}}, {"allele_fraction": "0.1263", "cds_effect": "423G>C", "depth": "665", "equivocal": "false", "functional_effect": "missense", "gene": "SUFU", "percent_reads": "12.63", "position": "chr10:104309832", "protein_effect": "M141I", "status": "unknown", "strand": "+", "transcript": "NM_016169", "dna_evidence": {"sample": "SQ_US1143571.01_1"}}, {"allele_fraction": "0.498", "cds_effect": "824A>C", "depth": "992", "equivocal": "false", "functional_effect": "missense", "gene": "NTRK1", "percent_reads": "49.8", "position": "chr1:156841521", "protein_effect": "E275A", "status": "unknown", "strand": "+", "transcript": "NM_002529", "dna_evidence": {"sample": "SQ_US1143571.01_1"}}, {"allele_fraction": "0.4482", "cds_effect": "1468C>T", "depth": "705", "equivocal": "false", "functional_effect": "missense", "gene": "TYRO3", "percent_reads": "44.82", "position": "chr15:41862523", "protein_effect": "R490C", "status": "unknown", "strand": "+", "transcript": "NM_006293", "dna_evidence": {"sample": "SQ_US1143571.01_1"}}, {"allele_fraction": "0.2367", "cds_effect": "35G>A", "depth": "811", "equivocal": "false", "functional_effect": "missense", "gene": "KRAS", "percent_reads": "23.67", "position": "chr12:25398284", "protein_effect": "G12D", "status": "known", "strand": "_", "transcript": "NM_004985", "dna_evidence": {"sample": "SQ_US1143571.01_1"}}, {"allele_fraction": "0.2344", "cds_effect": "427G>A", "depth": "964", "equivocal": "false", "functional_effect": "missense", "gene": "P2RY8", "percent_reads": "23.44", "position": "chrX:1585025", "protein_effect": "A143T", "status": "unknown", "strand": "_", "transcript": "NM_178129", "dna_evidence": {"sample": "SQ_US1143571.01_1"}}, {"allele_fraction": "0.2063", "cds_effect": "186_187insGCCGCAGCG", "depth": "252", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "MSH3", "percent_reads": "20.63", "position": "chr5:79950732", "protein_effect": "A62_P63insAAA", "status": "unknown", "strand": "+", "transcript": "NM_002439", "dna_evidence": {"sample": "SQ_US1143571.01_1"}}, {"allele_fraction": "0.128", "cds_effect": "309C>A", "depth": "719", "equivocal": "false", "functional_effect": "missense", "gene": "FGF6", "percent_reads": "12.8", "position": "chr12:4554428", "protein_effect": "D103E", "status": "unknown", "strand": "_", "transcript": "NM_020996", "dna_evidence": {"sample": "SQ_US1143571.01_1"}}, {"allele_fraction": "0.4975", "cds_effect": "56_57insAACTTCTTCCT", "depth": "605", "equivocal": "false", "functional_effect": "frameshift", "gene": "CASP8", "percent_reads": "49.75", "position": "chr2:202123010", "protein_effect": "G20fs*18", "status": "likely", "strand": "+", "transcript": "NM_001080125", "dna_evidence": {"sample": "SQ_US1143571.01_1"}}, {"allele_fraction": "0.7166", "cds_effect": "1428C>G", "depth": "681", "equivocal": "false", "functional_effect": "missense", "gene": "FLCN", "percent_reads": "71.66", "position": "chr17:17118503", "protein_effect": "D476E", "status": "unknown", "strand": "_", "transcript": "NM_144997", "dna_evidence": {"sample": "SQ_US1143571.01_1"}}]}, "copy_number_alterations": null, "rearrangements": {"rearrangement": {"description": "NBN(NM_002485) rearrangement intron 1", "equivocal": "false", "in_frame": "unknown", "other_gene": "N/A", "pos1": "chr8:90996560_90996922", "pos2": "chr8:91010502_91010670", "status": "unknown", "supporting_read_pairs": "16", "targeted_gene": "NBN", "type": "rearrangement", "dna_evidence": {"sample": "SQ_US1143571.01_1"}}}, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "7.57", "status": "intermediate", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}